<DOC>
	<DOC>NCT00001990</DOC>
	<brief_summary>To facilitate provision of atovaquone (566C80) to patients who have severe Pneumocystis carinii pneumonia (PCP) and are intolerant and/or unresponsive to trimethoprim / sulfamethoxazole ( TMX / SMX ); to monitor serious adverse events attributable to 566C80.</brief_summary>
	<brief_title>An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia, Pneumocystis</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Pentamidine</mesh_term>
	<mesh_term>Atovaquone</mesh_term>
	<mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
	<criteria>Inclusion Criteria Patients must have the following: Clinical diagnosis of acute severe Pneumocystis carinii pneumonia (PCP). Doselimiting intolerance to TMP / SMX and parenteral pentamidine. Willingness and ability to give informed consent. Exclusion Criteria Coexisting Condition: Excluded: Patients with a history of intolerance to 566C80. Patients with the following prior conditions are excluded: History of serious doselimiting adverse experience during previous 566C80 therapy, thought to be attributable to the drug. Required: Trimethoprim / sulfamethoxazole (TMP/SMX); pentamidine.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1993</verification_date>
	<keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
	<keyword>Pneumonia, Pneumocystis carinii</keyword>
	<keyword>Pentamidine</keyword>
	<keyword>Antifungal Agents</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>atovaquone</keyword>
</DOC>